Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13846352 | 0.87 | LCK (0.39) | MAPTKMT2ALCK | |
| SCHEMBL2910691 | 0.87 | LCK (0.40) | MAPTKMT2AMEN1LCKRAB9A | |
| SCHEMBL2926337 | 0.86 | LCK (0.39) | MAPTAKR1C3AKR1C2LCK | |
| SCHEMBL27980424 | 0.84 | AKR1C3 (0.38) | MAPTALDH1A1THRBAKR1C3AKR1C2 | |
| SCHEMBL2923527 | 0.81 | MAPT (0.44) | MAPTALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL2912520 | 0.81 | LCK (0.46) | MAPTALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL2920980 | 0.80 | MAPT (0.40) | MAPTALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL2921480 | 0.80 | MAPT (0.42) | MAPTALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL8077962 | 0.80 | CFTR (0.40) | MAPTALDH1A1KMT2ATP53LCK | |
| SCHEMBL27980423 | 0.80 | AKR1C3 (0.38) | MAPTALDH1A1THRBAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883833-B2 | Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-11-11 | — | — | US | disclosed |
| US-8883833-B2 | Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-11-11 | — | — | US | disclosed |
| US-20140275553-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2014-09-18 | — | — | US | disclosed |
| US-20140275553-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2014-09-18 | — | — | US | disclosed |
| US-20120207729-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2012-08-16 | — | — | US | disclosed |
| US-20120207729-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2012-08-16 | — | — | US | disclosed |
| EP-2225215-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | Decode Genetics EHF (IS) | 2010-09-08 | — | — | EP | disclosed |
| EP-2225216-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | Decode Genetics EHF (IS) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009067618-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067604-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
| US-20090130077-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | disclosed |
| US-20090130077-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | disclosed |
| US-20090130076-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | disclosed |
| US-20090130076-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130076-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | MAPT 4489/4885ALDH1A1 330/4885THRB 3940/4885 |
| US-20090130077-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4B, PDE4A, PDE3B | MAPT 3128/4885ALDH1A1 229/4885THRB 3629/4885 |
| US-20120207729-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | MAPT 4489/4885ALDH1A1 330/4885THRB 3940/4885 |
| US-20140275553-A1 | SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE3B, PDE4B, PDE4A | MAPT 4489/4885ALDH1A1 330/4885THRB 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.